Amerikanische Gesellschaft für Hirudotherapie

Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide

Research article published in Thrombosis and haemostasis (1994)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Observational studyArzneimittelentwicklungRomisch J et al. · Thrombosis and haemostasis, 1994

Abstract

The specific thrombin inhibitors r-hirudin and a synthetic peptide (I) D-FPRP(G)4-NGDFEEIPEEYL were compared in in vitro tests. r-hirudin proved to be the superior compound with respect to inhibition of amidolytic small substrate turnover that is catalysed by soluble and immobilised thrombin as well as to inhibition of fibrinogen activation. In an in vitro clot model significantly higher molar concentrations of peptide I are needed to achieve fibrin bound thrombin inhibition equivalent to that of r-hirudin. Stable complexes consisting of thrombin and hirudin oppose labile complexes containing the synthetic peptide. The latter leads to a regaining of thrombin activity with subsequent additional fibrin accretion. Analyses of the mixtures of thrombin and peptide I display a time dependent release of amino-terminal D-FPR peptide (III) exhibiting, similar to the residual fragment (peptide II), only weak inhibitory activity. Peptide I and the carboxy-terminal fragment induce, within a certain concentration range, an increase in thrombin activity and clot growth.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal Article
Indexed MeSH termsAmino Acid SequenceBlood CoagulationFibrinHirudinsHumansMolecular Sequence DataPeptide FragmentsRecombinant ProteinsStructure-Activity RelationshipThrombinTime Factors

Zusammenfassung

Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide.

Warum dies für die Hirudotherapie relevant ist

This study compared the specific thrombin inhibitors r-hirudin and a synthetic peptide (D-FPRP(G)4-NGDFEEIPEEYL) in in vitro tests of amidolytic substrate turnover, fibrinogen activation, and an in vitro clot model. r-Hirudin was the superior compound, forming stable thrombin–hirudin complexes, whereas the synthetic peptide formed labile complexes that allowed thrombin activity to resume and, within certain concentration ranges, even increased thrombin activity and clot growth. The findings highlight differences in complex stability and durability, but the abstract describes only 'in vitro tests' without specifying the blood source and does not involve live leeches or clinical outcomes; the relevance to hirudotherapy is limited to characterizing recombinant hirudin's properties.

Zitation

Inhibition of in vitro clot growth by r-hirudin is more effective and longer sustained than by an analogous peptide

Romisch J et al. · Thrombosis and haemostasis, 1994

DOIPubMed

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.